SHR 7390Alternative Names: SHR7390
Latest Information Update: 06 Jun 2017
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Jun 2017 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in China (NCT03182673)
- 16 Nov 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (In adults; In the elderly; Late-stage disease) in China (NCT02968485)
- 01 Nov 2016 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease) in China (PO) (NCT02968485)